Analysis of the polycythemia vera onset mechanism by investigating STAT5-target genes
| Project/Area Number |
23790096
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Biological pharmacy
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
TAGO Megumi 慶應義塾大学, 薬学部, 講師 (30445192)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | JAK2 / V617F 点変異 / 真性赤血球増加症 / STAT5 / c-Myc / ODC / Aurka / 慢性骨髄増殖性腫瘍 / JAK2V617F変異体 / シグナル伝達 |
|---|
| Research Abstract |
A point mutant of a tyrosine kinase JAK2 (V617F), which is a cause gene of polycythemia vera, induces cell proliferation and tumorigenesis through activation of a transcription factor STAT5. In this study , we found that a transcription factor
|
Report
(3 results)
Research Products
(29 results)
